Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition
Alcon
Develops, manufactures, and distributes comprehensive eye care products including surgical equipment, contact lenses, lens care solutions, and pharmaceutical products, and is expanding into cell therapy for retinal disease.
Company Info
Sector:Ophthalmology Devices & Surgical
Headquarters:Geneva, Switzerland
Founded:1945
Website:www.alcon.com/
Clinical Development Pipeline
NT-501
Target: Encapsulated cell therapy implant (CNTF)Unity VCS
Target: Combined surgical visualization platformHydrus Microstent
Target: Micro-invasive glaucoma surgery implantRecent News
Leadership Team
David J. Endicott
Chief Executive Officer
Ian Bell
President, Global Business & Innovation